Aghazadeh Behzad 4
4 · IMMUNOMEDICS INC · Filed Jun 11, 2019
Insider Transaction Report
Form 4
IMMUNOMEDICS INCIMMU
Aghazadeh Behzad
Director10% OwnerOther
Transactions
- Award
Common Stock, $0.01 par value per share (''Common Stock'')
2019-06-07+9,667→ 13,516 total - Award
Stock Option (right to buy)
2019-06-07+17,077→ 17,077 totalExercise: $12.93From: 2020-06-07Exp: 2026-06-07→ Common Stock, par value $0.01 per share (17,077 underlying)
Holdings
- 20,000,000(indirect: See footnotes)
Common Stock
Footnotes (5)
- [F1]Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2019 annual meeting of stockholders, which occurred on June 7, 2019.
- [F2]Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer.
- [F3]The stock options vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer.
- [F4]Such securities are held on behalf of accounts managed by Avoro Capital Advisors LLC (formerly venBio Select Advisor LLC), a Delaware limited liability company (the "Investment Manager") and Avoro Life Sciences Fund LLC (formerly venBio Select Fund LLC), a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager.
- [F5]The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.